Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Cognitive deficits have been identified as one of core clinical symptoms of major depressive disorder (MDD). Accumulating evidence indicated that triglycerides (TG) might be associated with MDD and cognitive decline.
Objective: This study examined whether patients with MDD had poorer cognitive functions than healthy controls, and further investigate whether TG levels were involved in MDD, and its cognitive impairments in a Han Chinese population.
Method: 115 patients with MDD and 119 healthy controls were enrolled. Cognitive functions were assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and serum TG levels were examined using enzymatic colorimetry.
Results: TG levels were higher in patients with MDD than healthy controls after controlling for the variables. Cognitive test scores were lower in patients with MDD than healthy controls except for visuospatial/constructional index after controlling for the variables. TG levels were negatively correlated with visuospatial/constructional score, delayed memory score and RBANS total score of MDD. Further multivariate regression analysis showed that TG levels were negatively associated with visuospatial/constructional score, attention score, delayed memory score and RBANS total score of MDD.
Conclusions: Our findings supported that serum TG levels might be involved in MDD, and play an important role in cognitive impairments of MDD, especially in delayed memory. Moreover, patients with MDD experienced greater cognitive impairments than healthy controls except for visuospatial/constructional index.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.comppsych.2017.03.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vortioxetine for Major Depressive Disorder in Children: 12-Week Randomized, Placebo-Controlled Study.
JAACAP Open
September 2025
H. Lundbeck A/S, Copenhagen, Denmark.
Objective: To evaluate efficacy, safety, and tolerability of vortioxetine in children ages 7 to 11 years with major depressive disorder.
Method: Patients meeting criteria for incomplete improvement in depressive symptoms (Children's Depression Rating Scale-Revised [CDRS-R] total score ≥40 plus <40% reduction and Parent Global Assessment Global Improvement score >2) after 4 weeks of single-blind lead-in treatment with a brief psychosocial intervention plus placebo were randomized 1:1:1:1 to 8-week double-blind treatment with brief psychosocial intervention and placebo, vortioxetine 10 mg/day, vortioxetine 20 mg/day, or fluoxetine 20 mg/day. Following preplanned interim analysis, enrollment to fluoxetine was stopped, and patients were randomized 1:1:1 to placebo, vortioxetine 10 mg, or vortioxetine 20 mg.
Vortioxetine Improves Brain Glymphatic System Function, Functional Connectivity, and Cognitive Functions in Major Depressive Disorder.
Depress Anxiety
September 2025
Medical Imaging Center, First Affiliated Hospital of Jinan University, Guangzhou, China.
The therapeutic effects of vortioxetine on mood and cognition have been documented in major depressive disorder (MDD). This study aims to examine whether vortioxetine can improve brain glymphatic system function and connections among functional brain networks and to explore the underlying relationships among these changes. A total of 34 patients with MDD and 41 healthy controls (HCs) were recruited in the study.
View Article and Find Full Text PDFComplete mitochondrial DNA sequence analysis in patients with major depressive disorder.
J Affect Disord
September 2025
Department of Psychiatry, The Affiliated Kangning Hospital of Ningbo University, Ningbo Kangning Hospital, Ningbo, China; Medical Center, Ningbo University, Ningbo, China. Electronic address:
Objective: This study aimed to identify potential mutations associated with major depressive disorder (MDD) and evaluate disease-associated risk factors.
Methods: Total genomic DNAwas extracted from the participants' blood samples, and the complete mitochondrial genome wasamplified by PCR, purified, and sequenced. Mutation burden analysis and functional mutation analysis was performed, including total mutation counts, highly conserved mutations (Conservation Index >75 %), and structurally disruptive mutations.
Transdiagnostic homogeneity, and diagnostic-specific biomarkers among major depressive disorder, bipolar disorder and schizophrenia during 40 Hz auditory steady-state response: a normative modeling analysis.
J Affect Disord
September 2025
Tianjin University, Medical School, Tianjin, China; Tianjin University, Haihe Laboratory of Brain-Computer Interaction and Human-Machine Integration, Tianjin, China; Tianjin University, State Key Laboratory of Advanced Medical Materials and Medical Devices, Tianjin, China.
Background: Abnormal gamma-band auditory steady-state response (gamma-ASSR) power has been reported in major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SZ), but distinguishing between these disorders based solely on power remains challenging. Directed functional connectivity (DFC), which captures topological patterns of causal information flow, may provide more diagnostic-specific markers. However, conventional case-control framework often disregards the substantial individual heterogeneity, yielding unreliable biomarkers.
View Article and Find Full Text PDFPatient-reported efficacy of adjunctive brexpiprazole in major depressive disorder in a phase 4, open-label, interventional study.
Curr Med Res Opin
September 2025
Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.
Objectives: In ENGAGE, patients with major depressive disorder (MDD) demonstrated improvements in patient-reported depression and life engagement while taking adjunctive brexpiprazole. This analysis aimed to further characterize patient perspectives on the effects of adjunctive brexpiprazole, using patient diary data from ENGAGE, and describe development of a 'word of the day' activity.
Methods: Prior to ENGAGE, word lists describing a 'good,' 'average,' and 'bad' day with depression were generated from semi-structured interviews with patients with MDD.